Ortholevo, Inc. Company Profile

Background

Overview

Ortholevo, Inc. is a privately held biotechnology company founded in 2016 and headquartered in Lexington, Massachusetts. The company is dedicated to developing non-surgical therapies aimed at treating fibrotic diseases affecting joints, muscles, lungs, and connective tissues. Ortholevo's mission is to improve the lives of patients worldwide by providing innovative treatments for conditions such as neuromuscular diseases, post-COVID-19 pulmonary fibrosis, musculoskeletal and congenital disorders, cosmetic ailments, and inflammatory diseases.

Mission and Vision

Ortholevo's mission is to enhance patient quality of life by offering effective, non-surgical treatments for fibrotic diseases. The company's vision is to become a leader in fibrosis therapy, providing accessible and safe solutions for a wide range of fibrotic conditions.

Primary Area of Focus

Ortholevo focuses on the development of non-surgical therapies targeting the RXFP1 receptor to treat fibrosis in various tissues, including joints, muscles, lungs, and connective tissues. This approach aims to address the underlying causes of fibrosis, offering patients an alternative to invasive surgical procedures.

Industry Significance

The biotechnology industry is continually evolving, with a growing emphasis on developing non-invasive treatments for chronic conditions. Ortholevo's innovative approach positions it as a significant player in the fibrosis therapy market, addressing a substantial unmet need for effective non-surgical treatments.

Key Strategic Focus

Core Objectives

Ortholevo's strategic objectives include:

• Advancing the development of its non-surgical fibrosis therapies.

• Conducting comprehensive preclinical and clinical studies to validate the efficacy and safety of its treatments.

• Securing regulatory approvals to bring its therapies to market.

• Establishing strategic partnerships to enhance research and development capabilities.

Specific Areas of Specialization

The company specializes in:

• Non-surgical treatments for fibrotic diseases.

• Targeting the RXFP1 receptor to modulate fibrosis.

• Developing therapies for conditions such as joint contracture, pulmonary fibrosis, and musculoskeletal disorders.

Key Technologies Utilized

Ortholevo employs advanced biotechnological methods, including:

• Recombinant protein production for therapeutic agents.

• Microparticle formulation for sustained drug release.

• Preclinical models to assess therapeutic efficacy and safety.

Primary Markets or Conditions Targeted

Ortholevo targets the following markets and conditions:

• Neuromuscular Diseases: Conditions leading to muscle fibrosis and contractures.

• Post-COVID-19 Pulmonary Fibrosis: Lung fibrosis resulting from COVID-19 infection.

• Musculoskeletal and Congenital Conditions: Disorders causing joint and tissue fibrosis.

• Cosmetic Ailments: Skin fibrosis and related cosmetic concerns.

• Inflammatory Diseases: Conditions leading to tissue fibrosis due to chronic inflammation.

Financials and Funding

Funding History

Ortholevo has secured funding through various grants and awards, including:

• May 2024: Received a grant from MassVentures to support the development of its fibrosis therapies.

• August 2024: Awarded $504,965 by the U.S. Small Business Administration (SBA) for the late-stage development of sustained-release relaxin for treating joint contracture.

Total Funds Raised

The company has raised approximately $5 million in non-dilutive grants from agencies such as the National Institutes of Health (NIH) and the Department of Defense (DOD).

Notable Investors

Key investors include:

• MassVentures: Provided funding in May 2024 to support Ortholevo's research and development efforts.

Intended Utilization of Capital

The capital raised is intended for:

• Advancing preclinical and clinical studies.

• Scaling up manufacturing processes for therapeutic agents.

• Securing regulatory approvals for market entry.

• Expanding research and development capabilities.

Pipeline Development

Key Pipeline Candidates

Ortholevo's primary pipeline candidate is:

• Sustained-Release Relaxin (SR-RLX): A therapeutic agent designed to treat joint contracture by modulating fibrosis.

Stages of Clinical Trials or Product Development

The SR-RLX therapy is in the late stages of preclinical development, with plans to initiate clinical trials upon successful completion of preclinical studies.

Target Conditions

The therapy targets:

• Joint Contracture: A condition characterized by the permanent tightening of muscles and tendons, leading to restricted movement.

Relevant Timelines for Anticipated Milestones

• 2024: Completion of preclinical studies and initiation of clinical trials.

• 2025: Submission of Investigational New Drug (IND) application to the FDA.

• 2026: Expected commencement of Phase I clinical trials.

Technological Platform and Innovation

Proprietary Technologies

Ortholevo's proprietary technologies include:

• Relaxin-2 Loaded Microparticle Formulation: Designed for sustained drug release at the site of fibrosis.

• RXFP1 Receptor Modulation: Targeting the RXFP1 receptor to regulate fibrosis progression.

Significant Scientific Methods

The company employs:

• Protein Therapeutics: Utilizing recombinant proteins for therapeutic applications.

• Microparticle Drug Delivery Systems: Ensuring controlled and sustained release of therapeutic agents.

• Preclinical Models: Assessing the efficacy and safety of therapies in animal models.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed, Ortholevo's focus on innovative drug delivery systems and receptor targeting suggests potential integration of advanced computational modeling and data analysis techniques in its research and development processes.

Leadership Team

Key Executive Profiles

• Edward Rodriguez: Co-founder and CEO. An orthopedic trauma surgeon with over 20 years of experience, specializing in treating trauma-related conditions such as arthrofibrosis.

• Ara Nazarian: Co-founder and Vice Chair of Orthopaedic Research at Beth Israel Deaconess Medical Center and Associate Professor at Harvard Medical School. Expert in musculoskeletal translational research and innovation.

• Davey Bakhshi: Co-founder and CEO of FORTEFAi. Experienced in biomedical devices, life sciences, and AI companies.

• Benjamin Cooper: Co-founder and CEO. Background in biomedical devices and life sciences.

• Mark Grinstaff: Founder. Expertise in biomedical engineering and drug delivery systems.

• Phillip Harding: Associate Director of Drug Development. Experienced in pharmaceutical development and regulatory affairs.

• Ophelie Puissegur: Associate Director of Clinical Development. Background in clinical trial management and regulatory submissions.

• Edward Ahn: Principal Investigator. Specialist in orthopedic research and clinical studies.

• Ken Rodriguez: Founder. Background in biomedical devices and life sciences.

Leadership Changes

As of February 2026, there are no publicly available records of recent significant changes or appointments within Ortholevo's leadership team.

Competitor Profile

Market Insights and Dynamics

The fibrosis therapy market is characterized by:

• Growing Incidence: An increasing number of patients suffering from fibrotic diseases globally.

• High Unmet Need: Limited availability of effective non-surgical treatments for fibrosis.

• Competitive Landscape: Presence of both established medical device companies and emerging biotech firms developing fibrosis therapies.

Competitor Analysis

Ortholevo's key competitors include:

• Orthofix Medical Inc.: A global medical device company specializing in spine and limb reconstruction.

• DJO LLC: Develops and distributes orthopedic equipment, including bone growth stimulators.

• Zimmer Biomet Holdings Inc.: Offers a comprehensive portfolio of orthopedic implants and related products.

• Bioventus LLC: Provides orthobiologic solutions for musculoskeletal healing.

Strategic Collaborations and Partnerships

Ortholevo has established collaborations with:

• Beth Israel Deaconess Medical Center: For research and clinical development support.

• Harvard Medical School: For academic and research collaboration.

Operational Insights

Ortholevo differentiates itself through:

• Non-Surgical Approach: Offering non-invasive treatments for fibrosis.

• Targeted Therapy: Focusing on the RXFP1 receptor to modulate fibrosis.

• Innovative Drug Delivery: Utilizing sustained-release formulations for localized treatment.

Strategic Opportunities and Future Directions

Ortholevo's strategic roadmap includes:

• Advancing Clinical Development: Completing preclinical studies and initiating clinical trials for SR-RLX.

• Regulatory Approvals: Securing IND approval and progressing through clinical trial phases.

• Market Expansion: Exploring additional indications for fibrosis therapies.

• Partnerships: Seeking strategic alliances for commercialization and distribution.

Contact Information

• Official Website: www.ortholevo.com

• LinkedIn Profile: Ortholevo, Inc.

Note: Contact details such as email addresses and physical addresses have been omitted as per the user's instructions.